Published in Medical Letter on the CDC and FDA, January 15th, 2006
The U.S. phase III clinical trial of Miraxion in Huntington disease commenced dosing in September, 2005.
Rick Stewart, CEO of Amarin, commented: "The commencement of the 240 patient European phase III clinical trial in Huntington's disease is a major milestone for Amarin. The U.S. trial of 300 patients is now well underway and we expect the European trial will show similar positive progress as patient enrollment accelerates."
Miraxion has Orphan Drug designation in the U.S. and in Europe. Additionally,...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.